Clinical Trials Logo

Clinical Trial Summary

Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus (HBV) co-infected with hepatitis delta virus (HDV).


Clinical Trial Description

The study is designed to evaluate safety and efficacy of MXB in a subset of HBV infected patients who are co-infected with HDV. Hepatitis delta represents the most severe form of chronic viral hepatitis and there is no approved treatment option available for patients infected with both HBV and HDV.

24 patients will be randomised into 3 arms: pre-treatment with MXB followed by PEG-INF-a treatment versus a combination of both drugs versus PEG-INF-a.

Prolonged blockade of HBV entry into hepatocytes should also block infection with HDV particles (which uses hepatitis B surface antigen (HBsAg) as its envelope) and thus provide a therapeutic option for this otherwise hardly treatable disease. PEG-INF-a is used for the treatment of chronic hepatitis delta. The study endpoints are virological response (HBsAg, hepatitis delta virus ribonucleic acid (HDV RNA), hepatitis B virus deoxyribonucleic acid (HBV DNA)), as well as safety and tolerability and drug immunogenicity. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02637999
Study type Interventional
Source Hepatera Ltd.
Contact
Status Completed
Phase Phase 1/Phase 2
Start date February 13, 2014
Completion date January 21, 2016

See also
  Status Clinical Trial Phase
Completed NCT05827146 - Study of Hepalatide in Chronic Hepatitis D(CHD) Patients Phase 2
Completed NCT02430181 - Lonafarnib With and Without Ritonavir in HDV (LOWR-1) Phase 2
Recruiting NCT05765344 - Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function Phase 1
Recruiting NCT05760300 - A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function Phase 1
Recruiting NCT06248580 - Find HDV and Determine Its Status in Turkey
Recruiting NCT05718700 - Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
Recruiting NCT04638439 - The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection Phase 1
Completed NCT02430194 - Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2) Phase 2